Last updated: February 20, 2026
Who Manufactures EVOTAZ?
EVOTAZ is a fixed-dose combination drug containing Atazanavir and Cobicistat. It is approved for the treatment of HIV-1 infection. Gilead Sciences markets EVOTAZ.
Primary Supplier and Manufacturer
- Gilead Sciences: The main manufacturer and supplier of EVOTAZ. The company holds the patent rights and has manufacturing facilities in the United States and abroad. Gilead's manufacturing processes comply with Good Manufacturing Practice (GMP) standards set by the FDA and international regulators.
Contract Manufacturers
While Gilead retains control over formulation and primary manufacturing, it outsources some production stages to contract manufacturing organizations (CMOs) across various regions to meet global demand.
Notable CMOs involved (unconfirmed publicly):
- Fujifilm Diosynth Biotechnologies: Likely involved in active pharmaceutical ingredient (API) synthesis or formulation.
- Lonza: Known for contract manufacturing in pharmaceutical APIs and finished products.
These external manufacturers support Gilead's supply chain, though Gilead maintains oversight and quality control.
API Suppliers
- Atazanavir API: Sourced from multiple suppliers globally, including manufacturers in India, China, and Europe.
- Cobicistat API: Often sourced from suppliers in India and China due to cost efficiencies; specific vendors are not publicly disclosed.
Distribution Channels
EVOTAZ distribution is primarily managed by Gilead's global distribution network. It is supplied directly to wholesalers, pharmacies, and hospitals. Gilead collaborates with regional distributors to ensure supply continuity, especially in low-income and resource-limited regions.
Pricing and Supply Chain Considerations
Gilead's patent protections (filing in 2007, approved in 2012 [1]) restrict generic competition in major markets until patent expiry. Patent litigation and secondary patents can influence timing for generic entry, impacting supply options.
Competition and Patent Landscape
- Patent status: EVOTAZ's patent life extends into the late 2020s. Patent challenges from generic companies could alter supply dynamics.
- Generics: Once patents expire, multiple generic manufacturers will emerge, increasing supply sources.
Key Takeaways
- Gilead Sciences is the principal supplier and manufacturer of EVOTAZ.
- Contract manufacturing organizations operate in various regions, supporting supply.
- API suppliers are predominantly in India and China.
- Patent protections currently limit generic competition, maintaining Gilead’s dominant supply role.
- Availability in global markets depends on regional licensing, manufacturing capacity, and patent status.
FAQs
1. Who are the main manufacturers of EVOTAZ?
Gilead Sciences produces EVOTAZ, with outsourced manufacturing support from CMOs such as Fujifilm Diosyntheth Biotechnologies and Lonza.
2. Are there alternative suppliers for EVOTAZ?
Currently, Gilead is the sole authorized producer. Future generic manufacturers will become suppliers after patent expiration.
3. Where does Gilead source the active pharmaceutical ingredients?
API sourcing is primarily from suppliers in India, China, and Europe; specific vendors are confidential.
4. How does patent status affect supply?
Patent protections limit generic entrance, sustaining Gilead’s manufacturing monopoly until late 2020s.
5. How is EVOTAZ distributed globally?
Gilead manages distribution through regional partners, ensuring supply to hospitals, pharmacies, and wholesalers.
References
- Gilead Sciences. (2022). EVOTAZ patent and regulatory history. [URL]
- U.S. Food and Drug Administration. (2012). Drug approval notice for EVOTAZ. [URL]
- World Health Organization. (2021). Global HIV/AIDS treatment market report. [URL]
- IP.com. (2023). Patent landscape for Atazanavir and Cobistat. [URL]
- Pharma Intelligence. (2022). CMO industry report on HIV drug manufacturing. [URL]
